Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

specific

Stage II includes: IIA: (T2, N0, M0, G3); (T2, N0, M0, GX); IIB: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)

18

Centers

14

Active Trials

Cancer Funding

Top Centers for Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8(18)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
74.0
2
NCI Comprehensive
Active Research Program
57.8
3
NCI Comprehensive
Active Research Program
57.8
4
NCI Comprehensive
Active Research Program
57.8
557.8
6
NCI Comprehensive
Active Research Program
57.8
7
NCI Comprehensive
Active Research Program
57.8
8
Active Research Program
57.8
9
NCI Comprehensive
Active Research Program
57.8
10
NCI Clinical
Active Research Program
57.8
11
Active Research Program
57.8
12
Active Research Program
57.8
13
Active Research Program
57.8
14
NCI Comprehensive
36.5
1536.5
1636.5
1736.5
1836.5

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →